Background and Aims: The impact of vedolizumab, a gut-selective monoclonal antibody, on postoperative outcomes is unclear. This study aimed to assess the impact of preoperative vedolizumab treatment on the rate of postoperative complications in patients with inflammatory bowel disease [IBD] undergoing abdominal surgery. Methods: A systematic search of multiple electronic databases from inception until May 2017 identified studies reporting rates of postoperative complications in vedolizumab-treated IBD patients compared to no biologic exposure or anti-tumor necrosis factor (anti-TNF) treated IBD patients. Outcomes of interest included postoperative infectious complications and overall postoperative complications. Pooled risk ratios and 95% confidence intervals were estimated using the random-effects model. Conclusions: Preoperative vedolizumab treatment in IBD patients does not appear to be associated with an increased risk of postoperative infectious or overall postoperative complications compared to either preoperative anti-TNF therapy or no biologic therapy. Future prospective studies which include perioperative drug level monitoring are needed to confirm these findings.
Introduction
Inflammatory bowel diseases [IBDs] , which include Crohn's disease [CD] and ulcerative colitis [UC] , are chronic and incurable disorders characterized by inflammation of the gastrointestinal tract. Over 1.2 million individuals have a diagnosis of IBD in North America and the worldwide prevalence of this disease is projected to increase exponentially in the next decade. 1 A wide range of treatments for IBD are available, including 5-aminosalicylates, corticosteroids, immunomodulators and biologics. IBD management was revolutionized by the introduction of anti-tumour necrosis factor [anti-TNF] agents in the late 1990s. The widespread adoption of anti-TNF agents resulted in lower rates of surgery and enhanced the quality of lives of patients with disease refractory to conventional therapy. 1 Since then, the armamentarium of biologic therapies has continued to evolve, expanding to encompass alternative mechanisms to anti-TNF agents. Vedolizumab, a humanized monoclonal antibody to α4β7 integrin, is one of these promising new medications and was recently approved for the treatment of moderate to severe CD and UC in North America and Europe. [2] [3] [4] Its gut-selective mechanism has brought great enthusiasm for this biologic, and initial studies have shown it to be safe and effective in the treatment of UC and CD. 5, 6 Despite the increasing number of medical therapies available for the treatment of IBD, it is estimated that up to 75% of patients with CD 7 and 20-30% of patients with UC will require surgery in their lifetime for medically refractory disease or its complications. 8 While vedolizumab has generally been shown to have a favourable safety profile, 9, 10 its impact in the perioperative setting remains unclear. Concerns for increased postoperative complications have been raised because vedolizumab targets leukocyte migration, a necessary component of wound healing. Theoretically, wound healing could be impaired, and, in turn, increase the risk of postoperative infections and other complications. 11 This attention has garnered several recent studies on this topic which have reported conflicting results. [11] [12] [13] [14] [15] [16] [17] To date, no meta-analyses have been published on this topic. Therefore, the aim of this systematic review and meta-analysis was to assess the impact of preoperative vedolizumab treatment on the rate of postoperative complications in patients with IBD undergoing abdominal surgery.
Methods
This systematic review and meta-analysis was conducted with guidance from the Cochrane handbook 18 and reported according to the Preferred Reporting Items for Systematic Reviews and meta-analyses [PRISMA] guidelines. 19 The process followed an a priori established protocol. 
Data sources and search strategy

Study selection
Interventional and observational studies were deemed acceptable for inclusion in the meta-analysis. Studies reporting rates of postoperative complications in IBD patients treated with preoperative vedolizumab compared to IBD patients treated with either anti-TNF medications or no biologic therapy were included. Studies were excluded if they lacked a non-vedolizumab-treated comparison cohort, or if the study population comprised paediatric patients alone. In situations where studies contained any overlapping data from the same patient population, only the study with the largest sample size was included. The methodological quality of the included studies was evaluated using the Newcastle-Ottawa Scale [NOS] 20 for observational studies and the Cochrane risk of bias tool 18 for randomized control trials. In the NOS, studies were scored across three categories: selection, comparability of study groups and ascertainment of the outcome of interest. The maximum score is 9. Studies with a score of 7 of higher were deemed as high quality, consistent with several other meta-analyses. [21] [22] [23] In the Cochrane risk of bias tool, studies were deemed to be at high, low or unclear risk of bias based on adequacy of sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other biases.
Outcomes of interest
Statistical analysis
Meta-analyses were conducted by combining individual study data into a pooled risk ratio [RR] . Intention-to-treat data were of interest and extracted from each study. Heterogeneity was assessed using the chi-squared and I 2 tests. The chi-squared test suggests substantial heterogeneity between studies when the p-value is less than 0.10.
18
The I 2 test describes how much variability between effect estimates is due to heterogeneity rather than chance. An I 2 test result greater than 50% suggests substantial heterogeneity. 18 We planned to use a random-effects model if there was substantial heterogeneity present, and a fixed effects model if it was not present. For assessment of publication bias, we created a funnel plot for studies that reported our primary outcome. We also planned to determine Egger's regression intercept provided at least 10 studies could be identified. 
Results
Search results
The literature search identified 993 citations, of which 983 were excluded on review of the titles and abstracts. An additional two abstracts were identified after a manual search of conference proceedings. Seven studies were excluded after careful review of the full text; four did not include a control group, 16, [25] [26] [27] two included data which overlapped with another larger study 11, 28 and one included paediatric patients only. 29 Overall, five studies with 1332 participants were eligible for meta-analysis. The process of study identification, inclusion and exclusion is summarized in Figure 1 .
Characteristics of included studies
Characteristics of the studies included are outlined in Table 1 . Overall, 307 vedolizumab-treated patients, 490 anti-TNF-treated patients and 535 patients not exposed to preoperative biologic therapy were included in the analysis. In Ferrante et al., 12 the no biologic group included patients on mesalamine, topical steroids, a low dose of systemic steroids [oral < 20 mg/day or oral > 20 mg/day for less than 2 months], thiopurines, methotrexate, calcineurin inhibitors, antibiotics or no therapy. In Schils et al., 14 the no biologic group included patients who were on any therapy except biologics or systemic steroids. Medications included in the no biologic therapy groups were not explicitly stated in Yamada et al., 17 Lightner et al. 13 or Shen et al. 15 Four studies were retrospective [12] [13] [14] 17 and one study was a post-hoc analysis of a randomized control trial. 15 All five studies compared preoperative vedolizumab to no biologic therapy. Four studies compared preoperative vedolizumab to preoperative anti-TNF therapy. [12] [13] [14] 17 Three studies reported a mixed cohort of IBD patients, 13, 15, 17 one study comprised patients with UC only 12 and one study comprised patients with CD only.
14 Because few studies stratified outcomes by IBD subtype, there were insufficient data to conduct subgroup analyses for UC and CD patients separately. The postoperative follow-up period was 30 days in all the studies, except Shen et al. where it was not specified. 15 All patients in this metaanalysis underwent abdominal or perianal surgery but there was variation in the specific types of surgeries included in each study. The maximum time elapsed between the last dose of vedolizumab and surgery ranged from 4 to 16 weeks. 
Overall postoperative complications
The pooled RR for overall postoperative complications in patients who received preoperative vedolizumab vs no biologic therapy was 
Study quality and publication bias
Study quality was assessed using the NOS for the four observational studies and the Cochrane risk of bias tool for the one post-hoc analysis of a randomized control trial. The four observational studies were high quality, with a median NOS score of 8 [range 8-9] out of a maximum score of 9. As Shen et al. 15 was a post-hoc analysis of the GEMINI I 5 and GEMINI II 6 trials, the Cochrane risk of bias tool was applied to those two studies. In both, there was a low-risk of bias with regard to sequence generation, allocation concealment, blinding, selective reporting and other biases. The risk of bias from incomplete data was unclear. Publication bias was not detected based on visual inspection of the funnel plot [ Supplementary Figure 1 ].
Discussion
Vedolizumab, a humanized monoclonal antibody to α4β7 integrin, has been shown to be safe and effective in the treatment of UC and CD. 5, 6 However, the risk of postoperative complications in the setting of vedolizumab therapy remains controversial and, to date, there are no other meta-analyses on this topic. The results of our systematic review and meta-analysis suggest that preoperative vedolizumab treatment is not associated with an increased risk of postoperative infectious or overall postoperative complications compared to either preoperative anti-TNF therapy or no biologic therapy.
The current literature in this field is limited to mainly observational experiences, consisting largely of case series, several chartreviews and one post-hoc analysis of a large randomized control trial. [11] [12] [13] [14] [15] [16] [17] [25] [26] [27] [28] There is also an ongoing prospective study examining postoperative complications in IBD patients exposed to biologic agents prior to surgery [the PUCCINI study]. 30 The results of the presently available studies have been mixed. Our results are in conflict with those of Lightner et al. 13 one of the largest studies to examine the risk of postoperative complications in patients treated with vedolizumab. They reported a significantly higher rate of surgical site infections in patients treated preoperatively with vedolizumab compared to those who received anti-TNF therapy [odds ratio 5.78; 95% CI 2.99-11.76]. 13 On the other hand, several studies have shown no difference in postoperative complication rates. 12, 14, 15, 17, 28 Of note, the absolute rate of overall postoperative complications in vedolizumabtreated patients reported by Lightner et al. 13 does not appear to be vastly higher than the rates reported by Ferrante et al. 12 and Yamada et al. 17 As shown in appear to be much lower in Lightner et al. 13 In Ferrante et al., the rate of overall postoperative complications was 48% in anti-TNFtreated patients and 56% in patients not treated with biologics. 12 Likewise, the rate of overall postoperative complications reported by Yamada et al. was 31% in anti-TNF-treated patients and 36% in patients not treated with biologics. 17 Hence, Lightner et al.'s findings may have been driven in part by lower postoperative outcomes in the anti-TNF and no biologic treatment comparison groups rather than a true association between preoperative vedolizumab therapy and increased postoperative complications. Nonetheless, the contradictory results in the current literature emphasize an urgent need for clarity on this subject.
We acknowledge several limitations of the literature contributing to our meta-analysis. There were some differences in the types of surgery included in each study. For example, Yamada et al. 17 included both minor and major abdominal procedures, Ferrante et al. 12 studied only colectomies, and Lightner et al. 13 examined only major abdominal surgeries. Moreover, the proportion of emergent vs elective surgeries was inconsistently reported by individual studies. Unsurprisingly, procedures with a greater degree of surgical complexity are associated with a higher risk of postoperative complications 31 and emergency surgery has been demonstrated to be a risk factor for death and postoperative complcations independent of preoperative comorbidities. 32, 33 These are important factors that will need to be addressed in future studies.
Another limitation of the analysis is the variation in the length of time between the patients' last dose of vedolizumab and surgery. Depending on the study, this time period ranged from 4 to 16 weeks. In addition, none of the studies explicitly stated the dose and frequency of vedolizumab administration. These factors could potentially lead to great variability in each patient's systemic concentration of vedolizumab at the time of surgery and thus on the impact of the medication on postoperative recovery. None of the studies reported measuring preoperative vedolizumab concentrations. Studies which quantify patients' exposure to vedolizmab such as through perioperative drug level monitoring would be helpful in this situation.
Concomitant steroid and immunosuppressive use may also have been a potential source of bias. Information on concurrent medication use was not available in every study. In the studies by Yamada et al. 17 and Lightner et al., 13 significantly higher rates of concurrent steroid use were noted in patients treated with veodlizumab than in patients in the other groups. Given that these therapies are associated with increased postoperative infections, the possibility of our results being confounded by concomitant medications is another important limitiation to consider. Ideally, patients taking concurrent steroids and immunosuppressive therapy would be excluded from the analysis. However, this may not be practical in the clinical setting as many patients using biologics may require combination therapy due to their disease severity or to lower immunogenicity.
While most studies stated the proportion of IBD patients with CD and UC, few reported their results for CD and UC patients separately. Thus, we were unable to perform planned subgroup analyses for patients with CD or UC only. Moreover, the location and behaviour of patients' disease were not consistently reported. No studies reported subgroup analyses stratified by characteristics such as penetrating disease, stricturing disease or perianal involvement only. Due to the limited sample sizes of the studies, subgroup analyses of this nature may not have been feasible. However, given that the inflammatory burden is not equal across different disease subtypes, this would an important distinction in future studies.
The strength of this meta-analysis is also limited by the design of the included studies. Of all eligible studies, only one collected data prospectively. With all retrospective studies, the influence of unmeasured confounding variables cannot be excluded. Furthermore, our results contained substantial heterogeneity. Meta-analyses on preoperative anti-TNF treatment and postoperative complications have also displayed substantial amounts of heterogeneity 22, 34, 35 and the literature on vedolizumab appears to be following this pattern. Some of the observed heterogeneity may be due to the paucity of studies and modest sample sizes. Indeed, the impact of vedolizumab on postsurgical outcomes is a relatively new area of research. However, the amount of literature on this topic is rapidly expanding and as larger and more robust studies are conducted, clearer trends may materialize.
Study or Subgroup
In conclusion, preoperative exposure to vedolizumab in IBD patients undergoing abdominal surgery does not appear to significantly increase the risk of postoperative infectious and overall postoperative complications. The results of this study provide some clarity to a controversial topic. However, these findings should be interpreted cautiously given the study's limited scope and the heterogeneity of the results. Larger prospective cohorts which include perioperative drug level monitoring would be valuable to more accurately and definitively examine the impact of preoperative vedolizumab on the risk of surgical complications in IBD patients. The results of the ongoing PUCCINI study may soon help shine further light on this issue. 30 Prescribing patients vedolizumab, especially those who are likely to require surgery in the near future, warrants astute, case-by-case judgement. In patients already taking vedolizumab, the decision to perform or, conversely, delay surgery requires careful weighing of the benefits of the procedure with the potential for postoperative complications.
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